Literature DB >> 7713276

Metabolic and drug distribution studies do not support direct inhibitory effects of metformin on intestinal glucose absorption.

J C Cuber1, A Bosshard, H Vidal, F Vega, N Wiernsperger, J R Rapin.   

Abstract

In an attempt to clarify the question of an involvement of the inhibition of intestinal glucose absorption in the mechanism of action of Metformin, we used several experimental approaches: 1 glucose/lactate measurement in rat portal blood in vivo and 2 in the venous effluent of an isolated perfused rat intestinal segment; 3 metabolism of freshly isolated enterocytes in vitro and tissue distribution of 3H-labeled Metformin was investigated both in vivo and in vitro. Metformin applied intraluminally had no significant effect on portal glycaemia after a glucose load, but lactate increased, whereas in vivo only a high Metformin dosage reduced portal glucose appearance significantly. Although high Metformin concentrations were found in gut biopsies, precise histological analysis in the isolated intestine revealed that it was absent from enterocytes; however the drug accumulated in villous lacteals. Intrarterially applied Metformin decreased glucose absorption in the isolated perfused ileo-jejunal segment. These data suggested that vascular Metformin boosted intestinal anaerobic glucose metabolism. Biochemical measurements performed on freshly isolated enterocytes showed that even high Metformin levels did not interfere with cell respiration or with Na+/K+ ATPase activity. Thus, our data agree with other recent reports, suggesting that even at nontherapeutic concentrations Metformin has no relevant inhibitory effect on intestinal glucose absorption. The data are discussed in the frame of previous divergent observations. The results suggest however that Metformin of vascular origin stimulates glucose consumption by the intestine, which then increases lactate output from the gut.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7713276

Source DB:  PubMed          Journal:  Diabete Metab        ISSN: 0338-1684


  6 in total

Review 1.  Cardiovascular impact of drugs used in the treatment of diabetes.

Authors:  Chris R Triggle; Hong Ding
Journal:  Ther Adv Chronic Dis       Date:  2014-11       Impact factor: 5.091

Review 2.  A risk-benefit assessment of metformin in type 2 diabetes mellitus.

Authors:  H C Howlett; C J Bailey
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

3.  Glucose supply and insulin demand dynamics of antidiabetic agents.

Authors:  Scott V Monte; Jerome J Schentag; Martin H Adelman; Joseph A Paladino
Journal:  J Diabetes Sci Technol       Date:  2010-03-01

4.  High and typical 18F-FDG bowel uptake in patients treated with metformin.

Authors:  Eric Gontier; Emmanuelle Fourme; Myriam Wartski; Cyrille Blondet; Gerald Bonardel; Elise Le Stanc; Marina Mantzarides; Herve Foehrenbach; Alain-Paul Pecking; Jean-Louis Alberini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-05       Impact factor: 9.236

Review 5.  Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review.

Authors:  A Natali; E Ferrannini
Journal:  Diabetologia       Date:  2006-02-14       Impact factor: 10.122

Review 6.  Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin.

Authors:  Malcolm J Borg; Christopher K Rayner; Karen L Jones; Michael Horowitz; Cong Xie; Tongzhi Wu
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.